文献速递疼痛医学

PF-06372865(α2/α3/α5亚型选择性GABAA部分激动剂)在人体中的镇痛潜力

Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans.
PubMed 文献 · Br J Anaesth · 2019-01-31

本研究在20名健康受试者中开展随机安慰剂对照交叉试验,评估PF-06372865(15 mg和65 mg)与普瑞巴林300 mg的镇痛效果。结果显示15 mg PF-06372865提高压力痛耐痛阈(比值1.11,90%CI 1.02-1.22),65 mg提高冷加压试验耐痛阈(比值1.17,90%CI 1.03-1.32)和压力痛耐痛阈(比值1.11,90%CI 1.01-1.21)。结论认为PF-06372865在未引起显著镇静或不可耐受不良事件的剂量下具有镇痛潜力。

要点

  • 15 mg PF-06372865提高压力痛耐痛阈,比值1.11(90%CI 1.02-1.22)。
  • 65 mg PF-06372865提高冷加压和压力痛耐痛阈,比值分别为1.17和1.11。
  • 普瑞巴林300 mg提高压力痛和冷加压耐痛阈,比值分别为1.15和1.31。

核心结论

  • PF-06372865在未引起显著镇静或其他不可耐受不良事件的剂量下具有镇痛潜力。
  • 本疼痛任务组合可作为新机制镇痛药开发中的工具,用于包括神经性疼痛在内的多种疼痛状态的概念验证。

研究设计与样本

  • 随机安慰剂对照交叉研究(NCT02238717),纳入20名健康受试者。
  • 比较PF-06372865 15 mg和65 mg与安慰剂及普瑞巴林300 mg(阳性对照)。
  • 使用一系列疼痛任务(电、压力、热、冷和炎性疼痛,包括条件性疼痛调制范式),在基线和给药后长达10小时进行药效学测量。

主要发现

  • 15 mg PF-06372865相比安慰剂增加压力痛耐痛阈(PTT),比值为1.11(90%CI 1.02,1.22)。
  • 65 mg PF-06372865增加冷加压试验PTT,比值为1.17(90%CI 1.03,1.32),并增加压力痛任务PTT,比值为1.11(90%CI 1.01,1.21)。
  • 普瑞巴林增加压力痛PTT,比值为1.15(95%CI 1.06,1.26),并增加冷加压任务PTT,比值为1.31(90%CI 1.16,1.48)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study investigated the analgesic effects of two doses (15 and 65 mg) of PF-06372865, a novel α2/α3/α5 gamma-aminobutyric acid A (GABAA) subunit selective partial positive allosteric modulator (PAM), compared with placebo and pregabalin (300 mg) as a positive control. METHODS: We performed a randomised placebo-controlled crossover study (NCT02238717) in 20 healthy subjects, using a battery of pain tasks (electrical, pressure, heat, cold and inflammatory pain, including a paradigm of conditioned pain modulation). Pharmacodynamic measurements were performed at baseline and up to 10 h after dose. RESULTS: A dose of 15 mg PF-06372865 increased pain tolerance thresholds (PTTs) for pressure pain at a ratio of 1.11 (90% confidence interval [CI]: 1.02, 1.22) compared with placebo. A dose of 65 mg PF-06372865 led to an increase in PTT for the cold pressor at a ratio of 1.17 (90% CI: 1.03, 1.32), and pressure pain task: 1.11 (90% CI: 1.01, 1.21). Pregabalin showed an increase in PTT for pressure pain at a ratio of 1.15 (95% CI: 1.06, 1.26) and cold pressor task: 1.31 (90% CI: 1.16, 1.48). CONCLUSION: We conclude that PF-06372865 has analgesic potential at doses that do not induce significant sedation or other intolerable adverse events limiting its clinical use. In addition, the present study established the potential role for this battery of pain tasks as a tool in the development of analgesics with a novel mechanism of action, for the treatment of various pain states including neuropathic pain and to establish proof-of-concept. CLINICAL TRIALS REGISTRATION: NCT0223871.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. van Amerongen G, Siebenga PS, Gurrell R, et al. Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans. Br J Anaesth. 2019. PMID: 30915991. doi:10.1016/j.bja.2018.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。